Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions 02/16/2024 The results of the clinical trial that led to FDA's 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions have been published. The drug shrank tumors in 80% of people receiving the drug as an initial treatment. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892